| Title
of the article |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
| Authors |
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; for the ACCOMPLISH Trial investigators. |
| Journal
|
Lancet. 2010 Feb 17. [Epub ahead of print] |
| Subject
Consultant |
P. Barany |
| Score
(1 to 3 stars) |
*** |
| Comments |
ACCOMPLISH was a double-blind, randomised trial of 11 506 patients with hypertension who were at high risk for cardiovascular events. Patients were randomly assigned to receive benazepril (20 mg) plus amlodipine (5 mg; n=5744) or benazepril (20 mg) plus hydrochlorothiazide (12.5 mg; n=5762), orally once daily. Progression of chronic kidney disease was defined as doubling of serum creatinine concentration or end-stage renal disease. The trial was terminated early (mean follow-up 2.9 years) because of superior efficacy of benazepril plus amlodipine compared with benazepril plus hydrochlorothiazide. There were 113 (2.0%) events of chronic kidney disease progression in the benazepril plus amlodipine group compared with 215 (3.7%) in the benazepril plus hydrochlorothiazide group (HR 0.52, 0.41-0.65, p<0.0001). |
